---
title: "MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290055475.md"
description: "A biotechnology company called MetaVia Inc., which focuses on transforming cardiometabolic diseases, revealed that its President and CEO, Hyung Heon Kim, is set to take part in a fireside chat. The company made this announcement today in Cambridge, Mass., dated June 17, 2026. MetaVia Inc. is listed on Nasdaq with the ticker symbol MTVA."
datetime: "2026-06-17T12:33:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290055475.md)
  - [en](https://longbridge.com/en/news/290055475.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290055475.md)
generator: "portal-rs"
---

# MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

A biotechnology company called MetaVia Inc., which focuses on transforming cardiometabolic diseases, revealed that its President and CEO, Hyung Heon Kim, is set to take part in a fireside chat. The company made this announcement today in Cambridge, Mass., dated June 17, 2026. MetaVia Inc. is listed on Nasdaq with the ticker symbol MTVA.

### Related Stocks

- [MTVA.US](https://longbridge.com/en/quote/MTVA.US.md)

## Related News & Research

- [Novartis pauses autoimmune cell therapy studies after deaths, WSJ reports](https://longbridge.com/en/news/297596287.md)
- [Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML | APVO Stock News](https://longbridge.com/en/news/297911849.md)
- [12:11 ETSpecialty Enzymes & Probiotics Launches SlimSEB™](https://longbridge.com/en/news/297939436.md)
- [Koala trial doses first patient with novel KMA‑targeting CAR‑T](https://longbridge.com/en/news/298021066.md)
- [TScan Therapeutics cuts workforce 75% in reorganization to focus on in vivo solid tumor cell therapy](https://longbridge.com/en/news/297773935.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**